ambroxol has been researched along with Chronic Disease in 23 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients." | 9.08 | [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis]. ( Michnar, M; Milanowski, J, 1996) |
| "In a double-blind, randomized, controlled trial using parallel groups, we evaluated the effects of two dose levels of ambroxol (60 and 120 mg daily) versus placebo by means of pulmonary function tests, patients' diary cards, interviews on current airway symptoms and subjective drug effects in 92 subjects with simple hypersecretory chronic bronchitis." | 9.06 | Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. ( Ericsson, CH; Jönsson, E; Juhasz, J; Mossberg, B, 1987) |
| "In a 6-month, double-blind multicenter trial conducted over the winter, the effects of daily administration of ambroxol retard (75 mg) were compared with those of placebo in preventing exacerbations and improving symptoms and clinical signs in chronic bronchitis patients." | 9.06 | Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. ( Bonsignore, G; Carnimeo, N; Catena, E; Chianese, R; Daniotti, S; Ferrara, G; Marcatili, S; Olivieri, D; Tomasini, G; Zavattini, G, 1987) |
| "Twenty-three patients with exacerbations of chronic bronchitis were divided in two groups in a randomized fashion receiving either amoxicillin 1500 mg/d (n = 13) or amoxicillin 1500 mg/d associated with the mucolytic drug ambroxol 90 mg/d (n = 10)." | 9.06 | Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. ( Corazza, C; Fernández, M; Guerreiro, RB; Peralta, J; Poderoso, JJ; Wiemeyer, JC, 1987) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 6.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol was associated with a 25% reduction of the average bronchial flow resistance." | 6.64 | [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]. ( Niemeyer, K; Wiessmann, KJ, 1978) |
| "Ninety-seven cases with chronic rhinosinusitis were randomly divided into three groups, with 31 cases in B group treated by ambroxol, 33 cases in C group treated by eucalyptol-limonene-pinene enteric soft capsule and 33 cases in control group (A group)." | 5.15 | [Clinical observation of mucoregulatory agents' application after chronic rhinosinusitis surgery]. ( Liu, L; Qian, J; Sun, J; Zhao, J, 2011) |
| "This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients." | 5.08 | [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis]. ( Michnar, M; Milanowski, J, 1996) |
| "In a double-blind, randomized, controlled trial using parallel groups, we evaluated the effects of two dose levels of ambroxol (60 and 120 mg daily) versus placebo by means of pulmonary function tests, patients' diary cards, interviews on current airway symptoms and subjective drug effects in 92 subjects with simple hypersecretory chronic bronchitis." | 5.06 | Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. ( Ericsson, CH; Jönsson, E; Juhasz, J; Mossberg, B, 1987) |
| "In a 6-month, double-blind multicenter trial conducted over the winter, the effects of daily administration of ambroxol retard (75 mg) were compared with those of placebo in preventing exacerbations and improving symptoms and clinical signs in chronic bronchitis patients." | 5.06 | Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. ( Bonsignore, G; Carnimeo, N; Catena, E; Chianese, R; Daniotti, S; Ferrara, G; Marcatili, S; Olivieri, D; Tomasini, G; Zavattini, G, 1987) |
| "Twenty-three patients with exacerbations of chronic bronchitis were divided in two groups in a randomized fashion receiving either amoxicillin 1500 mg/d (n = 13) or amoxicillin 1500 mg/d associated with the mucolytic drug ambroxol 90 mg/d (n = 10)." | 5.06 | Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. ( Corazza, C; Fernández, M; Guerreiro, RB; Peralta, J; Poderoso, JJ; Wiemeyer, JC, 1987) |
| "The clinical activity of trans-4-[(2-amino-3,5-dibromo-benzyl)-amino]-cyclohexanol-hydrochloride (ambroxol, NA 872) as well as its influence on lung function was examined in a total of 63 patients (34 suffering from silicosis, 28 from chronic obstructive bronchitis and 1 from cryptococcosis)." | 3.66 | [Therapeutic study on ambroxol in chronic bronchopulmonary diseases (author's transl)]. ( Curti, PC; Renovanz, HD, 1978) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 2.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol was associated with a 25% reduction of the average bronchial flow resistance." | 2.64 | [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]. ( Niemeyer, K; Wiessmann, KJ, 1978) |
| "Ambroxol is able to inhibit mediator release involved in the pathogenesis of allergic inflammation." | 2.41 | [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties]. ( Kuna, P; Kupczyk, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (65.22) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, J | 1 |
| Qian, J | 1 |
| Zhao, J | 1 |
| Liu, L | 1 |
| Ueda, T | 1 |
| Schöpp, W | 1 |
| Lusuardi, M | 1 |
| Capelli, A | 1 |
| Salmona, M | 1 |
| Tacconi, MT | 1 |
| Cerutti, CG | 1 |
| Donner, CF | 1 |
| Michnar, M | 1 |
| Milanowski, J | 1 |
| Ekberg-Jansson, A | 1 |
| Larsson, S | 1 |
| Löfdahl, CG | 1 |
| Aleksa, VI | 1 |
| Prozorova, VK | 1 |
| Mal'tseva, NA | 1 |
| Shatikhina, LN | 1 |
| Kupczyk, M | 2 |
| Kuna, P | 2 |
| Wiessmann, KJ | 1 |
| Niemeyer, K | 1 |
| Curti, PC | 1 |
| Renovanz, HD | 1 |
| Aliperta, A | 1 |
| Bellissimo, U | 1 |
| Turco, D | 1 |
| Antinolfi, G | 1 |
| Solopov, VN | 2 |
| Kolganova, NA | 2 |
| Cegla, UH | 1 |
| Ericsson, CH | 2 |
| Juhasz, J | 2 |
| Jönsson, E | 2 |
| Mossberg, B | 2 |
| Olivieri, D | 1 |
| Zavattini, G | 1 |
| Tomasini, G | 1 |
| Daniotti, S | 1 |
| Bonsignore, G | 1 |
| Ferrara, G | 1 |
| Carnimeo, N | 1 |
| Chianese, R | 1 |
| Catena, E | 1 |
| Marcatili, S | 1 |
| Dirksen, H | 1 |
| Hermansen, F | 1 |
| Groth, S | 1 |
| Mølgaard, F | 1 |
| Disse, BG | 1 |
| Calero del Castillo, JB | 1 |
| Pérez Martínez, F | 1 |
| Piqueras Pérez, F | 1 |
| Redondo Luciáñez, ER | 1 |
| Peralta, J | 1 |
| Poderoso, JJ | 1 |
| Corazza, C | 1 |
| Fernández, M | 1 |
| Guerreiro, RB | 1 |
| Wiemeyer, JC | 1 |
3 reviews available for ambroxol and Chronic Disease
| Article | Year |
|---|---|
[Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Topics: Acetylcysteine; Acute Disease; Ambroxol; Chronic Disease; Expectorants; Humans; Respiratory Tract Di | 2002 |
[Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Topics: Acetylcysteine; Acute Disease; Ambroxol; Antioxidants; Asthma; Chronic Disease; Expectorants; Humans | 2002 |
The pharmacology of ambroxol--review and new results.
Topics: Airway Resistance; Ambroxol; Animals; Bromhexine; Bronchitis; Chronic Disease; Humans; Infant, Newbo | 1987 |
13 trials available for ambroxol and Chronic Disease
| Article | Year |
|---|---|
[Clinical observation of mucoregulatory agents' application after chronic rhinosinusitis surgery].
Topics: Adolescent; Adult; Aged; Ambroxol; Chronic Disease; Cyclohexanols; Cyclohexenes; Eucalyptol; Expecto | 2011 |
[Efficacy of combined drug therapy using a macrolide antibiotic and an antihistamine for adult patients with chronic paranasal sinusitis].
Topics: Adult; Ambroxol; Anti-Bacterial Agents; Chronic Disease; Dibenzazepines; Drug Therapy, Combination; | 2003 |
Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol.
Topics: Ambroxol; Bronchi; Bronchitis; Bronchoalveolar Lavage Fluid; Chronic Disease; Double-Blind Method; E | 1995 |
[Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis].
Topics: Administration, Oral; Adult; Aged; Ambroxol; Anti-Bacterial Agents; Bronchitis; Chronic Disease; Cou | 1996 |
[Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)].
Topics: Adult; Aged; Airway Resistance; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials a | 1978 |
Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Doubl | 1989 |
[Comparative evaluation of the effectiveness of lasolvan and mucodine in chronic nonspecific lung diseases].
Topics: Ambroxol; Asthma; Bromhexine; Bronchitis; Carbocysteine; Chronic Disease; Clinical Trials as Topic; | 1988 |
[Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients].
Topics: Administration, Oral; Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as T | 1988 |
Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function.
Topics: Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1987 |
Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo.
Topics: Adult; Ambroxol; Bacterial Infections; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as T | 1987 |
Mucociliary clearance in early simple chronic bronchitis.
Topics: Adult; Ambroxol; Bronchi; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Mucociliary | 1987 |
Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function.
Topics: Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1986 |
Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Amoxicillin; Blood Gas Analysis; Bromhexine; Bronchitis; C | 1987 |
7 other studies available for ambroxol and Chronic Disease
| Article | Year |
|---|---|
[Long-term treatment of chronic bronchitis with ambroxol].
Topics: Adult; Aged; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Drug Administration Schedule; Drug E | 1981 |
Preventing exacerbations of chronic bronchitis and COPD.
Topics: Acetylcysteine; Adjuvants, Immunologic; Ambroxol; Antioxidants; Bacteria; Bronchitis; Cell Extracts; | 2001 |
[Effectiveness of lasolvan in patients with chronic obstructive bronchitis and non-atopic bronchial asthma].
Topics: Adult; Ambroxol; Asthma; Bronchitis; Chronic Disease; Expectorants; Humans; Injections, Intramuscula | 2001 |
[Therapeutic study on ambroxol in chronic bronchopulmonary diseases (author's transl)].
Topics: Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Cryptococcosis; Humans; Lung Diseases; Lung Disea | 1978 |
Normalization of bronchial exocrine pathology after endobronchial treatment with ambroxol.
Topics: Adult; Aged; Ambroxol; Biopsy; Bromhexine; Bronchi; Bronchitis; Bronchoscopy; Chronic Disease; Exocr | 1986 |
[Incorporation of a stimulant of the synthesis and secretion of pulmonary surfactant (ambroxol) in the medical treatment of serous otitis].
Topics: Acoustic Impedance Tests; Acute Disease; Adolescent; Adult; Ambroxol; Bromhexine; Child; Child, Pres | 1988 |
[Effect of lasolvan on mucociliary transport in patients with chronic nonspecific lung diseases].
Topics: Adhesiveness; Ambroxol; Bromhexine; Chronic Disease; Drug Evaluation; Humans; Lung Diseases; Mucocil | 1988 |